Navigation Links
Ground Zero Pharmaceuticals Announces Expansion of Regulatory Consulting Services to South Africa
Date:10/9/2007

ical, biologics, biotechnology and medical device industries. Some of its service portfolio includes regulatory representation and submissions (paper and electronic), preclinical planning, clinical consulting, biostatistics, chemistry, manufacturing and controls consulting, and medical writing. The GZP core team is located internationally, throughout the US, Canada, Australia and Europe.

For further information please contact Ms. Tisha Templeton, Vice President of Finance and Operations, Ground Zero Pharmaceuticals, Inc., +1-949-419-6136, fax, +1-949-852-3655, ttempleton@groundzerous.com.


'/>"/>
SOURCE Ground Zero Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
2. Death Wishes Influenced By Ethnicity and Racial Background
3. Fresh Cases of Bird-Flu Prepares the Ground for More Chicken Martyrs
4. Seizure of Low Quantity of Heroin is No Ground for Bail: HC
5. Groundbreaking Asthma Intervention Lessons Help Inner-City Children
6. AIIMS Campus - A Breeding Ground for Mosquitoes
7. A slum in Mumbai – breeding ground for disease
8. Underground Water Contamination In Tripura
9. Adequate Ground Work before a Pandemic Necessary
10. Hospital infections gaining ground in Pennsylvania hospitals
11. Underground Air - Associated With - DNA Damages
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2009)... NEW ORLEANS, Dec. 7 Cell Therapeutics, ... that Ruth Pettengell, M.D. of St. George,s Hospital, ... 2009 American Society of Hematology ("ASH") Annual Meeting ... (PIX 301) clinical trial of pixantrone (the "PIX ... non-Hodgkin,s lymphoma ("NHL") patients who have failed ...
(Date:12/6/2009)... ORLEANS and SUNNYVALE, Calif., Dec. 6 ... interim results from a Phase I/II study showing ... / recurrent non-Hodgkin,s Lymphoma (NHL) treated with its ... data were presented today at the 51st ASH ... (Abstract # 2726). ,, PCI-24781 is an ...
(Date:12/6/2009)... signs of feline DNA in virus , , SUNDAY, Dec. 6 ... AIDS might be found in a tiger that lived thousands ... It appears the virus took on a bit of a ... cat remains in the virus to this day. That tiger, ... evolution of the virus that ultimately led to its infection ...
(Date:12/6/2009)... ON. Dec. 6, 2009 A new study provides ... known as venous thromboembolism (VTE). , The condition ... every year, and occurs when an abnormal clot forms ... causing pain and swelling. In some cases, the clot ... through the heart to the lungs, causing a potentially ...
(Date:12/5/2009)... significant scientific advances in the field of blood cancers, ... of how certain diseases progress in order to discover ... care. Research presented today at the 51st Annual Meeting ... therapies for managing multiple myeloma, the importance of advance ...
Breaking Medicine News(10 mins):Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 2Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 3Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 4Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 5Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 2Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 3Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 4Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 5Health News:AIDS May Date Back to Ancient Tiger 2Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8
... Against Widex and William Demant Companies, SALT LAKE ... ), a leading producer of advanced digital hearing aids,issues ... of press,releases related to a jury award of $31 ... Inc. v. Sonic Innovations,Inc., et al. While this action ...
... The first genome-wide search for genes governing social behavior ... the amoebae Dictyostelium discoideum -- have more than 100 ... study by scientists at Rice University and Baylor College ... the journal Nature. It marks one of the first ...
... Senior Living Inc.,(NYSE: BKD ) announced today that ... 2007 financial results after the market closes on Wednesday,February ... to discuss,the results on February 28, 2008 at 10:00 ... (866) 845-7252 (from within the U.S.) or (706) 634-9069,(from ...
... at The Wistar Institute have collaborated on a major advance ... the deadliest cancers in humans. The culmination of 10 years ... new cancer therapies. , During much of its lifetime, ... in an inactive form, stored inside densely knotted structures in ...
... to close FMLA loopholes, ALEXANDRIA, Va., Feb. ... devoted to human resource management,appeared before a Senate ... the,Family Medical and Leave Act (FMLA) be closed., ... have two primary concerns with the act,s,regulations--the definitions ...
... first quarter operating results further convinces ... a discount, NEW YORK, Feb. 13 Accipiter ... 10% of the outstanding,shares of common stock of VistaCare, ... delivered a letter to VistaCare,s Board of Directors stating,that ...
Other Medicine News:Health News:Sonic Innovations Not Included in Adverse Jury Verdict 2Health News:Microbial 'cheaters' help scientists ID 'social' genes 2Health News:Microbial 'cheaters' help scientists ID 'social' genes 3Health News:Brookdale Announces Fourth Quarter and Full Year 2007 Release and Earnings Call 2Health News:Scientists solve structure of gene regulator that plays key role in cancer 2Health News:Scientists solve structure of gene regulator that plays key role in cancer 3Health News:Is a Common Cold a 'Serious Health Condition'? 2Health News:Accipiter Capital Management Reaffirms Its Opposition to the Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc. 2Health News:Accipiter Capital Management Reaffirms Its Opposition to the Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc. 3Health News:Accipiter Capital Management Reaffirms Its Opposition to the Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc. 4
(Date:12/6/2009)... RNL Bio Co., Ltd, ( www.rnl.co.kr ... stem cell therapeutics announced today that a 46-year-old ... after receiving stem cell treatment. Park was suffering ... affects the central nervous system (brain and spinal ... in which the nerves of the central nervous ...
(Date:12/4/2009)... (Pink Sheets: VRMLQ) announced that on December 3, 2009, it ... Disclosure Statement with the United States Bankruptcy Court for the ... the adequacy of the Disclosure Statement is presently scheduled for ... the Plan scheduled for January 7, 2010. ,, "We are ...
(Date:12/4/2009)... Corporation (Nasdaq: DYNT ) announced it has signed ... rehab supplies to Benchmark Physical Therapy with 65 clinics ... pleased to be named the sole-source supplier to Benchmark ... of sales and marketing at Dynatronics. "Benchmark is known ...
Breaking Medicine Technology:Multiple Sclerosis Patient Finds Hope Through Stem Cell Treatment 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 3Homecare Recipients and Providers to Rally against Cuts in IHSS Program 3B Hearing on Lawsuit in Oakland Federal Court Monday 59707 1Homecare Recipients and Providers to Rally against Cuts in IHSS Program 3B Hearing on Lawsuit in Oakland Federal Court Monday 59707 2Fine tuning treatments for depression 59705 1Fate Therapeutics announces creation of small molecule platform for commercial scale reprogramming 10409 1Fate Therapeutics announces creation of small molecule platform for commercial scale reprogramming 10409 2
... Novavax, Inc.,(Nasdaq: NVAX ) announced today favorable ... of its non-adjuvanted pandemic influenza virus-like,particle (VLP) vaccine ... and Head of Clinical,Development stated, "The initial results ... further development of our pandemic influenza vaccine,through regulatory ...
... Novel Biomarkers Displaying 90% Sensitivity in Breast ... ... announced today the,discovery and validation of the most frequent DNA alterations detected ... appeared in PLoS ONE. The study entitled, "Identification of,Novel High-Frequency DNA Methylation ...
Other Medicine Technology:Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program 2Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program 3Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program 4Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: